1Mass General Cancer Center, Harvard Medical School, Charlestown, Massachusetts. 2Department of Life Sciences, Korea University, Seoul, Republic of Korea.

1Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee. Search for other works by this author on: 2Department of Computational Biology, St. Jude Children’s Research ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

Copyright held by the owner/author(s).

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

1Genome Research Center, GC Genome, Yongin-si, South Korea. *Corresponding Author: Eun-Hae Cho, Genome Research Center, GC Genome, 107, Ihyeon-ro 30 beon-gil, Yongin-si, 16924, South Korea. E-mail: ...

Waltham, MA–based biotech Mural Oncology announced that it will end its phase III trial of nemvaleukin alfa, an engineered fusion protein that selectively binds to the intermediate-affinity IL2 ...

1Department of Communication, University of Utah, Salt Lake City, Utah. 2Huntsman Cancer Institute, Salt Lake City, Utah. *Corresponding Author: Yi Liao, Department of Communication, University of ...

Copyright held by the owner/author(s).

The acting director of the Centers for Disease Control and Prevention (CDC), Susan Monarez, PhD, has been nominated to lead the agency. Prior to moving to the CDC in January, Monarez, who’s held ...

Major Finding: Synonymous mutations can promote tumorigenesis by deregulating RNA modifications of tumor suppressors.

Boston, MA–based Dana-Farber Cancer Institute (DFCI) secured approval from the state to build a 300-bed hospital at the current site of the Joslin Diabetes Center in the city’s Longwood Medical Area.